Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia

NCT01625000 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.

NCT NCT01625000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01625000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia
Lead sponsor
Tanabe Pharma Corporation
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2012
Completion date
October 31, 2015
Enrollment
512 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia